The trajectory of companies tied to the drug's history presents a complex investment landscape. While the initial success generated substantial profits , generic alternatives have significantly eroded sales . Investing in associated pharmaceutical companies now requires a careful assessment of proprietary rights , evolving patient shifts , and the